

Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study

Eur Heart J (2005) 26;2520-3

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16249219

Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes

N Engl J Med (2006)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16537663

Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute

ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial

Jama (2006)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16537725

Excess dosing of antiplatelet and antithrombin agents in the treatment of

non-ST-segment elevation acute coronary syndromes K. P. Alexander, A. Y. Chen, M. T.

Roe, L. K. Newby, C. M. Gibson, N. M. Allen-LaPointe, C. Pollack, W. B. Gibler, E. M.

Ohman and E. D. Peterson

Jama (2005) 294;3108-16

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16380591

Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an

updated and comprehensive meta-analysis of 25 307 patients F. Andreotti, L. Testa, G.

Biondi-Zoccai and F. Crea

Eur Heart J (2005)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16143706

Influence of aspirin resistance on platelet function profiles in patients on long-term

aspirin and clopidogrel after percutaneous coronary intervention D. J. Angiolillo, A.

Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, P. Jimenez-Quevedo, R.

Hernandez, R. Moreno, J. Escaned, F. Alfonso, C. Banuelos, M. A. Costa, T. A. Bass

and C. Macaya

Am J Cardiol (2006) 97;38-43

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16377281

Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial

Infarction E. M. Antman, D. A. Morrow, C. H. McCabe, S. A. Murphy, M. Ruda, Z.

Sadowski, A. Budaj, J. L. Lopez-Sendon, S. Guneri, F. Jiang, H. D. White, K. A. Fox

and E. Braunwald

N Engl J Med (2006)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16537665

Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and

soluble CD40 ligand following percutaneous coronary interventions in patients with

stable coronary artery disease R. R. Azar, G. Badaoui, A. Sarkis, R. Kassab, E. Salame,

S. Klayme, R. Naman and M. Germanos

Am J Cardiol (2005) 95;236-40

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15642557

Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease R. R. Azar, R. Kassab, A. Zoghbi, S. Aboujaoude, H. El-Osta, P. Ghorra, M. Germanos and E. Salame
Am Heart J (2006) 151;521 e1-521 e4

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16442924

Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia J. A. Barrabes, D. Garcia-Dorado, M. Mirabet, J. Inserte, L. Agullo, B. Soriano, A. Massaguer, F. Padilla, R. M. Lidon and J. Soler-Soler

J Am Coll Cardiol (2005) 45;293-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15653030

Controversies in antiplatelet therapy for patients with cardiovascular disease E. R. Bates and W. C. Lau

Circulation (2005) 111;e267-71

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15867186

Sex differences in platelet reactivity and response to low-dose aspirin therapy D. M. Becker, J. Segal, D. Vaidya, L. R. Yanek, J. E. Herrera-Galeano, P. F. Bray, T. F. Moy, L. C. Becker and N. Faraday

Jama (2006) 295;1420-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16551714

Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial S. C. Beinart, P. Kolm, E. Veledar, Z. Zhang, E. M. Mahoney, O. Bouin, S. Gabriel, J. Jackson, R. Chen, J. Caro, S. Steinhubl, E. Topol and W. S. Weintraub

J Am Coll Cardiol (2005) 46;761-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16139122

The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial P. B. Berger, P. J. Best, E. J. Topol, J. White, P. M. DiBattiste, A. W. Chan, S. D. Kristensen, H. C. Herrmann and D. J. Moliterno

Am Heart J (2005) 149;869-75

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15894970

A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial D. L. Bhatt, K. A. Fox, W. Hacke, P. B. Berger, H. R. Black, W. E. Boden, P. Cacoub, E. A. Cohen, M. A. Creager, J. D. Easton, M. D. Flather, S. M.

Haffner, C. W. Hamm, G. J. Hankey, S. C. Johnston, K. H. Mak, J. L. Mas, G. Montalescot, T. A. Pearson, P. G. Steg, S. R. Steinhubl, M. A. Weber, J. Booth and E. J. Topol

Am Heart J (2005) 150;401

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16169314

Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events D. L. Bhatt, K. A. Fox, W. Hacke, P. B. Berger, H. R. Black, W. E. Boden, P. Cacoub, E. A. Cohen, M. A. Creager, J. D. Easton, M. D. Flather, S. M. Haffner, C. W. Hamm, G. J. Hankey, S. C. Johnston, K. H. Mak, J. L. Mas, G. Montalescot, T. A. Pearson, P. G. Steg, S. R. Steinhubl, M. A. Weber, D. M. Brennan, L. Fabry-Ribaudo, J. Booth and E. J. Topol

N Engl J Med (2006)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16531616

Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial L. Bolognese, G. Falsini, F. Liistro, P. Angioli, K. Ducci, T. Taddei, R. Tarducci, F. Cosmi, S. Baldassarre and A. Burali

J Am Coll Cardiol (2006) 47;522-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16458130

Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting K. A. Bybee, B. D. Powell, U. Valeti, A. G. Rosales, S. L. Kopecky, C. Mullany and R. S. Wright

Circulation (2005) 112;1286-92

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16159833

Fondaparinux in ST-Segment Elevation Myocardial Infarction: The Drug, the Strategy, the Environment, or All of the Above? R. M. Califf

Jama (2006)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16537724

Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study C. L. Campbell, P. B. Berger, G. A. Nuttall, J. L. Orford, P. J. Santrach, W. C. Oliver, M. H. Ereth, C. M. Thompson, M. K. Murphy, D. L. McGlassen, L. M. Schrader and S. R. Steinhubl

Am Heart J (2005) 150;796-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16209984

Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction--the RADIAL-AMI pilot randomized trial W. J. Cantor, G. Puley, M. K. Natarajan, V. Dzavik, M. Madan, A. Fry, H. H. Kim, J. L. Velianou, N. Pirani, B. H. Strauss and R. J. Chisholm

Am Heart J (2005) 150;543-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16169338

Comparison of the safety and efficacy of emboli prevention devices versus platelet glycoprotein IIb/IIIa inhibition during carotid stenting A. W. Chan, J. S. Yadav, D. L. Bhatt, C. T. Bajzer, P. A. Gum, M. Roffi, L. Cho, R. Agah and E. J. Topol
Am J Cardiol (2005) 95;791-5

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15757616

Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention W. H. Chen, P. Y. Lee, W. Ng, J. Y. Kwok, X. Cheng, S. W. Lee, H. F. Tse and C. P. Lau
Am J Cardiol (2005) 96;760-3

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16169354

Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial) D. P. Chew, A. M. Lincoff, H. Gurm, K. Wolski, D. J. Cohen, T. Henry, F. Feit and E. J. Topol
Am J Cardiol (2005) 95;581-5

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15721095

Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis M. J. Claeys, M. G. Van der Planken, J. M. Bosmans, J. J. Michiels, F. Vertessen, P. Van Der Goten, F. L. Wuyts and C. J. Vrints
Eur Heart J (2005) 26;567-75

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15618034

Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events J. P. Collet, G. Montalescot, G. Agnelli, F. Van de Werf, E. P. Gurfinkel, J. Lopez-Sendon, C. V. Laufenberg, M. Klutman, N. Gowda and D. Gulba
Eur Heart J (2005) 26;2285-93

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15932908

Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention P. A. Cowper, K. Udayakumar, M. H. Sketch, Jr. and E. D. Peterson
J Am Coll Cardiol (2005) 45;369-76

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15680714

Effectiveness of the concomitant use of bivalirudin and drug-eluting stents (from the prospective, multicenter BivAlirudin and Drug-Eluting STents [ADEST] study) G. Dangas, Z. Lasic, R. Mehran, D. Cox, M. G. Ghali, T. D. Henry, P. S. Teirstein, J. F. Stella, K. F. Browne, Jr., S. A. Lewis, W. Knopf, M. B. Leon, J. W. Moses and G. W. Stone

Am J Cardiol (2005) 96;659-63

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16125490

Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention G. B. Danzi, C. Capuano, M. Sesana, L. Mauri and F. B. Sozzi
Am J Cardiol (2006) 97;489-93

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16461043

Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting L. De Luca, G. De Persio, M. Minati, C. Iacoboni and F. Fedele

Am Heart J (2005) 149;1135

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15976799

Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy S. J. Denardo, K. E. Davis and J. E. Tcheng

Am Heart J (2005) 149;138-44

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15660045

Direct thrombin inhibitors M. Di Nisio, S. Middeldorp and H. R. Buller

N Engl J Med (2005) 353;1028-40

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16148288

Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: a new reperfusion strategy A. Dogan, M. Ozgul, M. Ozaydin, S. M. Aslan, O. Gedikli and A. Altinbas

Am Heart J (2005) 149;1037-42

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15976785

Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials J. W. Eikelboom, D. J. Quinlan, S. R. Mehta, A. G. Turpie, I. B. Menown and S. Yusuf

Circulation (2005) 112;3855-67

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16344381

Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel J. E.

Exaire, J. E. Tcheng, D. J. Kereiakes, N. S. Kleiman, R. J. Applegate and D. J.

Moliterno

Catheter Cardiovasc Interv (2005) 64;369-72

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15736260

Major bleeding complications in a specialized anticoagulation service J. Fanikos, N.

Grasso-Correnti, R. Shah, N. Kucher and S. Z. Goldhaber

Am J Cardiol (2005) 96;595-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16098319

Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices H. M. Farouque, J. A. Tremmel, F. Raissi Shabari, M. Aggarwal, W. F. Fearon, M. K. Ng, M. Rezaee, A. C. Yeung and D. P. Lee

J Am Coll Cardiol (2005) 45;363-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15680713

Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis E. Ferrari, M. Benhamou, P. Cerboni and B. Marcel

J Am Coll Cardiol (2005) 45;456-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15680728

Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial D. H. Fitchett, A. Langer, P. W. Armstrong, M. Tan, A. Mendelsohn and S. G. Goodman

Am Heart J (2006) 151;373-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16442903

The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale R. P. Giugliano, L. K. Newby, R. A. Harrington, C. M. Gibson, F. Van de Werf, P. Armstrong, G. Montalescot, J. Gilbert, J. T. Strony, R. M. Califf and E. Braunwald

Am Heart J (2005) 149;994-1002

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15976780

The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis R. Glaser, H. A. Glick, H. C. Herrmann and S. E. Kimmel

J Am Coll Cardiol (2006) 47;529-37

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16458131

Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization T. J. Gluckman, J. B. Segal, N. L. Fredde, K. E. Saland, J. T. Jani, J. M. Walenga, M. M. Prechel, K. M. Citro, D. A. Zidar, E. Fox, S. P. Schulman, T. S. Kickler and J. J. Rade

Am J Cardiol (2005) 95;744-7

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation>

[n&list_uids=15757601](#)

Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies J. Godicke, M. Flather, M. Noc, M. Gyongyosi, H. R. Arntz, L. Grip, H. M. Gabriel, K. Huber, F. Nugara, J. Schroder, L. Svensson, D. Wang, S. Zorman and G. Montalescot

Am Heart J (2005) 150;1015

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16290988

Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling S.

Goto, N. Tamura, H. Ishida and Z. M. Ruggeri

J Am Coll Cardiol (2006) 47;155-62

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16386680

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial A. B. Greenbaum, C. L. Grines, J. A. Bittl, R. C. Becker, D. J. Kereiakes, I. C. Gilchrist, J. Clegg, J. E. Stankowski, D. R. Grogan, R. A. Harrington, H. Emanuelsson and W. D. Weaver

Am Heart J (2006) 151;689 e1-689 e10

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16504633

Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study P. A. Gurbel, K. P. Bliden, K. Guyer, P. W. Cho, K. A. Zaman, R. P. Kreutz, A. K. Bassi and U. S. Tantry

J Am Coll Cardiol (2005) 46;1820-6

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16286165

The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting P. A. Gurbel, K. P. Bliden, K. M. Hayes, J. A. Yoho, W. R. Herzog and U. S. Tantry

J Am Coll Cardiol (2005) 45;1392-6

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15862408

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study P. A. Gurbel, K. P. Bliden, W. Samara, J. A. Yoho, K. Hayes, M. Z. Fissaha and U. S. Tantry

J Am Coll Cardiol (2005) 46;1827-32

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16286166

Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study P. A. Gurbel, K. P. Bliden, K. A. Zaman, J. A. Yoho, K. M. Hayes and U. S. Tantry

Circulation (2005) 111;1153-9

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation>

[n&list_uids=15738352](#)

Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center H. S. Gurm, V. Rajagopal, R. Fathi, D. Vivekanathan, J. S. Yadav, D. L. Bhatt, S. G. Ellis, A. M. Lincoff and E. J. Topol

Am J Cardiol (2005) 95;716-21

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15757596

Cilostazol improves long-term outcomes after coronary stent implantation Y. Han, S. Wang, Y. Li, Q. Jing, Y. Ma, J. Deng, G. Yang, H. Yu and J. Ge

Am Heart J (2005) 150;568

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16169342

Aspirin resistance G. J. Hankey and J. W. Eikelboom

Lancet (2006) 367;606-17

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16488805

Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention W.

Hochholzer, D. Trenk, D. Frundi, P. Blanke, B. Fischer, K. Andris, H. P. Bestehorn, H. J. Buttner and F. J. Neumann

Circulation (2005) 111;2560-4

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15809367

Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention R. Huang, J. Sacks, H. Thai, S. Goldman, D. A.

Morrison, C. Barbieri and J. Ohm

Catheter Cardiovasc Interv (2005) 65;25-33

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15800889

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y₁₂

antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind

comparison to clopidogrel with aspirin S. Husted, H. Emanuelsson, S. Heptinstall, P. M.

Sandset, M. Wickens and G. Peters

Eur Heart J (2006)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16476694

Frequency and Management of Thrombocytopenia With the Glycoprotein IIb/IIIa

Receptor Antagonists L. M. Huxtable, M. J. Tafreshi and A. N. Rakkar

Am J Cardiol (2006) 97;426-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16442410

Are tirofiban and abciximab identical in efficacy? F. H. Jafary

Eur Heart J (2006) 27;119-20

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16278228

Aspirin resistance and a single gene B. K. Jefferson, J. H. Foster, J. J. McCarthy, G.

Ginsburg, A. Parker, K. Kottke-Marchant and E. J. Topol

Am J Cardiol (2005) 95;805-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15757620

Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection M. Jonas, G. W. Stone, R. Mehran, J. Hermiller, R. Feldman, H. C. Herrmann, D. A. Cox, R. E. Kuntz, J. J. Popma and C. Rogers
Eur Heart J (2006)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16415300

Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache? E. I. Kapetanakis, D. A. Medlam, S. W. Boyce, E. Haile, P. C. Hill, M. K. Dillum, A. S. Bafi, K. R. Petro and P. J. Corso
Eur Heart J (2005) 26;576-83

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15723815

Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment: The ISAR-REACT 2 Randomized Trial A. Kastrati, J. Mehilli, F. J. Neumann, F. Dotzer, J. Ten Berg, H. Bollwein, I. Graf, M. Ibrahim, J. Pache, M. Seyfarth, H. Schühlen, J. Dirschinger, P. B. Berger and A. Schomig
Jama (2006)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16533938

Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months C. Katsouras, L. K. Michalis, N. Papamichael, K. Adamides, K. K. Naka, D. Nikas, J. A. Goudevenos and D. A. Sideris
Am Heart J (2005) 150;385-91

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16169312

Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: initial experience with intracoronary tenecteplase R. V. Kelly, E. Crouch, H. Krumnacher, M. G. Cohen and G. A. Stouffer
Catheter Cardiovasc Interv (2005) 66;327-32

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16208711

Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography R. Koos, A. H. Mahnken, G. Muhlenbruch, V. Brandenburg, B. Pflueger, J. E. Wildberger and H. P. Kuhl
Am J Cardiol (2005) 96;747-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16169351

Brachytherapy and bivalirudin evaluation study P. Kuchulakanti, R. Wolfram, R. Torguson, S. W. Rha, E. Cheneau, E. E. Pinnow, D. Canos, L. F. Satler, A. D. Pichard,

K. M. Kent and R. Waksman
Am Heart J (2005) 150;832-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16209990

Effect of adjunctive treatment with tirofiban on troponin T elevation during stenting of critically stenosed aortocoronary saphenous vein grafts V. Kurowski, R. Toelg, D. Jain, C. Richter, U. K. Wiegand, G. Richardt and A. A. Khattab

Am J Cardiol (2005) 96;681-4

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16125495

Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug B. Labarthe, P. Theroux, M. Angioi and M. Ghitescu

J Am Coll Cardiol (2005) 46;638-45

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16098428

Prehospital administration of enoxaparin before primary angioplasty for ST-elevation acute myocardial infarction J. N. Labeque, C. Jais, O. Dubos, M. Denard, M. Berhouet, L. Leroux, G. Laplace, C. Vergnes, C. Pradeau, M. Thicoipe, P. D. Santos and P. Coste
Catheter Cardiovasc Interv (2006) 67;207-13

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16416473

Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial A. J. Lansky, C. Pietras, R. A. Costa, Y. Tsuchiya, B. R. Brodie, D. A. Cox, E. D. Aymong, T. D. Stuckey, E. Garcia, J. E. Tcheng, R. Mehran, M. Negoita, M. Fahy, E. Cristea, M. Turco, M. B. Leon, C. L. Grines and G. W. Stone

Circulation (2005) 111;1611-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15811868

Safety of coronary stenting with eptifibatide and ultra-low-dose heparin M. Le May, M. Kurdi, M. Labinaz, C. Glover, D. So, S. Ryan and R. Davies

Am J Cardiol (2005) 95;630-2

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15721106

Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis S. W. Lee, S. W. Park, M. K. Hong, Y. H. Kim, B. K. Lee, J. M. Song, K. H. Han, C. W. Lee, D. H. Kang, J. K. Song, J. J. Kim and S. J. Park

J Am Coll Cardiol (2005) 46;1833-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16286167

Comparison of cilostazol and clopidogrel after successful coronary stenting S. W. Lee, S. W. Park, M. K. Hong, C. W. Lee, Y. H. Kim, J. H. Park, S. J. Kang, K. H. Han, J. J. Kim and S. J. Park

Am J Cardiol (2005) 95;859-62

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15781016

Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study M. Leoncini, A. Toso, M. Maioli, F. Bellandi, T. Badia, A. Politi, S. De Servi and R. P. Dabizzi
Am Heart J (2005) 150;401

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16169315

Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance E. I. Lev, R. T. Patel, K. J. Maresh, S. Guthikonda, J. Granada, T. DeLao, P. F. Bray and N. S. Kleiman
J Am Coll Cardiol (2006) 47;27-33

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16386660

Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study B. S. Lewis, S. R. Mehta, K. A. Fox, D. A. Halon, F. Zhao, R. J. Peters, M. Keltai, A. Budaj and S. Yusuf
Am Heart J (2005) 150;1177-84

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16338255

Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events) M. J. Lim, K. A. Eagle, J. M. Gore, F. A. Anderson, Jr., O. H. Dabbous, R. H. Mehta, C. B. Granger, K. A. Fox, F. A. Spencer and R. J. Goldberg
Am J Cardiol (2005) 96;917-21

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16188516

Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial) M. Madan, S. Radhakrishnan, M. Reis, F. L. Paradiso-Hardy, M. Godin-Edgecombe, C. Sparling, A. M. Phillips, S. Shanmugasagaram, S. Fort, S. Z. Naqvi and E. A. Cohen
Am J Cardiol (2005) 95;1295-301

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15904632

Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial K. W. Mahaffey and J. J. Ferguson
Am Heart J (2005) 149;S81-90

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16124952

Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation E. M. Mahoney, S. Mehta, Y. Yuan,

J. Jackson, R. Chen, S. Gabriel, A. Lamy, S. Culler, J. Caro, S. Yusuf and W. S. Weintraub

Am Heart J (2006) 151;219-27

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16368322

Facilitated primary coronary intervention with abciximab and very low dose of alteplase during off-hours compared with direct primary intervention during regular hours M.

Maioli, M. Gallopin, M. Leoncini, F. Bellandi, A. Toso and R. P. Dabizzi

Catheter Cardiovasc Interv (2005) 65;484-91

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15973688

Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease A. O. Maree, R. J. Curtin, M. Dooley, R. M. Conroy, P. Crean, D. Cox and D. J. Fitzgerald

J Am Coll Cardiol (2005) 46;1258-63

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16198840

Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for

Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial H. S. Markus, D.

W. Droste, M. Kaps, V. Larrue, K. R. Lees, M. Siebler and E. B. Ringelstein

Circulation (2005) 111;2233-40

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15851601

Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in

Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial S.

R. Mehta, P. G. Steg, C. B. Granger, J. P. Bassand, D. P. Faxon, J. I. Weitz, R. Afzal, B.

Rush, R. J. Peters, M. K. Natarajan, J. L. Velianou, D. M. Goodhart, M. Labinaz, J. F.

Tanguay, K. A. Fox and S. Yusuf

Circulation (2005) 111;1390-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15781750

Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus S. S. Mehta,

R. J. Silver, A. Aaronson, M. Abrahamson and A. B. Goldfine

Am J Cardiol (2006) 97;567-70

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16461058

Usefulness of preprocedural platelet aggregation to predict restenosis after

percutaneous coronary intervention S. Miyamoto, H. Kawano, T. Kudoh, H. Soejima, S.

Kojima, J. Hokamaki, H. Maruyoshi, T. Sakamoto, M. Yoshimura, Y. Ozaki and H.

Ogawa

Am J Cardiol (2005) 96;71-3

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15979437

Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome

D. Mukherjee, E. Kline-Rogers, J. Fang, K. Munir and K. A. Eagle

Heart (2005) 91;23-6

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15604326

Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up D. Mukherjee, E. J. Topol, M. E. Bertrand, S. D. Kristensen, H. C. Herrmann, F. J. Neumann, S. J. Yakubov, J. P. Bassand, R. R. McClure, G. W. Stone, D. Ardissino and D. J. Moliterno

Eur Heart J (2005) 26;2524-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16107485

Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment D. Mukherjee, E. J. Topol, D. J. Moliterno, D. M. Brennan, K. Ziada, L. Cho and S. R. Steinhubl

Heart (2006) 92;49-51

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15845611

Biliverdin administration prevents the formation of intimal hyperplasia induced by vascular injury A. Nakao, N. Murase, C. Ho, H. Toyokawa, T. R. Billiar and S. Kanno

Circulation (2005) 112;587-91

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16027253

A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions M. K. Natarajan, J. L. Velianou, A. G. Turpie, S. R. Mehta, D. Raco, D. M. Goodhart, R. Afzal and J. S. Ginsberg

Am Heart J (2006) 151;175

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16368313

Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction E. Nikolsky, H. M. Sadeghi, M. B. Effron, R. Mehran, A. J. Lansky, Y. Na, D. A. Cox, E. Garcia, J. E. Tchong, J. J. Griffin, T. D. Stuckey, M. Turco, J. D. Carroll, C. L. Grines and G. W. Stone

Am J Cardiol (2005) 96;474-81

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16098296

Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial E. M. Ohman, F. Van de Werf, E. M. Antman, R. M. Califf, J. A. de Lemos, C. M. Gibson, R. L. Oliverio, L. Harrelson, C. McCabe, P. DiBattiste and E. Braunwald

Am Heart J (2005) 150;79-88

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16084152

The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis B. Pamukcu, H. Oflaz and Y. Nisanci

Am Heart J (2005) 149;675-80

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15990752

A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy G. Parodi, R. Sciagra, A. Migliorini, G. Memisha, G. Moschi, R. Valenti, A. Pupi and D. Antoniucci

Am Heart J (2005) 150;220

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16086921

Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study G. Patti, G. Colonna, V. Pasceri, L. L. Pepe, A. Montinaro and G. Di Sciascio

Circulation (2005) 111;2099-106

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15750189

Association Between Level of Platelet Inhibition After Early Use of Abciximab and Myocardial Reperfusion in ST-Elevation Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention A. Perez de Prado, F. Fernandez-Vazquez, J. C. Cuellas, N. Alonso-Orcajo, R. Carbonell, C. Pascual, C. Olalla, A. Diego, A. de Miguel and R. G. Calabozo

Am J Cardiol (2006) 97;798-803

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16516579

Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine A. S. Petronio, M. De Carlo, N. Ciabatti, G. Amoroso, U. Limbruno, C. Palagi, V. Di Bello, M. F. Romano and M. Mariani

Am Heart J (2005) 150;1015

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16290987

The Charisma of Subgroups and the Subgroups of CHARISMA M. A. Pfeffer and J. A. Jarcho

N Engl J Med (2006)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16531617

Administration of intracoronary eptifibatid during ST-elevation myocardial infarction D. S. Pinto, A. J. Kirtane, N. A. Ruocco, A. J. Deibele, A. Shui, J. Buros, S. A. Murphy and C. M. Gibson

Am J Cardiol (2005) 96;1494-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16310428

Prior aspirin use and outcomes in elderly patients hospitalized with acute myocardial infarction E. L. Portnay, J. M. Foody, S. S. Rathore, Y. Wang, F. A. Masoudi, J. P. Curtis and H. M. Krumholz

J Am Coll Cardiol (2005) 46;967-74

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16168277

Use of abciximab prevents microcirculatory impairment in patients treated with coronary angioplasty for unstable angina: results of a prospective randomized study F. Prati, P. Kwiatkowski, C. Caroselli, F. Imola, A. Manzoli, T. Fouad, P. Corvo and V. Ramazzotti Catheter Cardiovasc Interv (2005) 66;165-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16142802

Clinical characteristics predict benefits from eptifibatid therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial J. A. Puma, L. T. Banko, K. S. Pieper, T. J. Sacchi, J. C. O'Shea, J. P. Dery and J. E. Tchong

J Am Coll Cardiol (2006) 47;715-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16487833

Glycoprotein IIb-IIIa receptor inhibition with eptifibatid in percutaneous intervention for symptomatic peripheral vascular disease: The circulate pilot trial K. J. Rocha-Singh and J. Rutherford

Catheter Cardiovasc Interv (2005) 66;470-3

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16284982

Initial experience with a new femoral artery closure device following percutaneous coronary intervention with glycoprotein IIb/IIIa inhibition P. N. Ruygrok, J. A. Ormiston, J. T. Stewart, M. W. Webster, S. El Jack, S. Simpson-Plaumann, I. P. Kay and T. M. Chou Catheter Cardiovasc Interv (2005) 66;185-91

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16152652

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation M. S. Sabatine, C. P. Cannon, C. M. Gibson, J. L. Lopez-Sendon, G. Montalescot, P. Theroux, M. J. Claeys, F. Cools, K. A. Hill, A. M. Skene, C. H. McCabe and E. Braunwald

N Engl J Med (2005) 352;1179-89

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15758000

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study M. S. Sabatine, C. P. Cannon, C. M. Gibson, J. L. Lopez-Sendon, G. Montalescot, P. Theroux, B. S. Lewis, S. A. Murphy, C. H. McCabe and E. Braunwald

Jama (2005) 294;1224-32

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16143698

Angiographic and Clinical Outcomes in Patients Receiving Low-Molecular-Weight Heparin Versus Unfractionated Heparin in ST-Elevation Myocardial Infarction Treated With Fibrinolytics in the CLARITY-TIMI 28 Trial M. S. Sabatine, D. A. Morrow, G. Montalescot, M. Dellborg, J. L. Leiva-Pons, M. Keltai, S. A. Murphy, C. H. McCabe, C.

M. Gibson, C. P. Cannon, E. M. Antman and E. Braunwald
Circulation (2005)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16291601

Inhibition of platelet aggregation with eptifibatid, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The Pharmacodynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study) J. F. Saucedo, W. Aude, R. Pacheco, B. Thorn, Z. Matin, K. Husain and L. Garza

Am J Cardiol (2005) 95;1453-6

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15950569

One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel A. Schomig, C. Schmitt, A. Dibra, J. Mehilli, C. Volmer, H. Schuhlen, J. Dirschinger, F. Dotzer, J. M. ten Berg, F. J. Neumann, P. B. Berger and A. Kastrati

Eur Heart J (2005) 26;1379-84

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15734767

Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials V. L. Serebruany, S. R. Steinhubl, P. B. Berger, A. I. Malinin, J. S. Baggish, D. L. Bhatt and E. J. Topol

Am J Cardiol (2005) 95;1218-22

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15877994

Variability in platelet responsiveness to clopidogrel among 544 individuals V. L. Serebruany, S. R. Steinhubl, P. B. Berger, A. I. Malinin, D. L. Bhatt and E. J. Topol
J Am Coll Cardiol (2005) 45;246-51

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15653023

Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting S. Silberman, C. Neukirch-Stoop and P. G. Steg

Am J Cardiol (2005) 95;509-10

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15695141

Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention P. R. Sinnaeve, J. Simes, S. Yusuf, J. Garg, S. Mehta, J. Eikelboom, J. A. Bittl, P. Serruys, E. J. Topol and C. B. Granger

Eur Heart J (2005) 26;2396-403

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16214829

Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction H. Steen, S. Lehrke, U. K. Wiegand, C. Merten, L. Schuster, G. Richardt, C. Kulke, H. B. Gehl, J. A. Lima, H. A. Katus and E. Giannitsis
Am Heart J (2005) 149;564

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15864217

Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention S. R. Steinhubl, P. B. Berger, D. M. Brennan and E. J. Topol

J Am Coll Cardiol (2006) 47;939-43

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16516075

Clopidogrel Treatment Prior to Percutaneous Coronary Intervention: When Enough Isn't Enough S. R. Steinhubl and R. Charnigo

Jama (2006)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16533936

Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial) T. D. Stuckey, G. W. Stone, D. A. Cox, J. E. Tcheng, E. Garcia, J. Carroll, G. Guagliumi, B. D. Rutherford, J. J. Griffin, M. Turco, A. J. Lansky, R. Mehran, M. Fahy, B. R. Brodie and C. L. Grines

Am J Cardiol (2005) 95;1-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15619385

Should aspirin be discontinued before coronary artery bypass surgery? J. C. Sun, M. A. Crowther, T. E. Warkentin, A. Lamy and K. H. Teoh

Circulation (2005) 112;e85-90

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16103244

What is the best measure of thrombotic risks-pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation? U. S. Tantry, K. P. Bliden and P. A. Gurbel

Catheter Cardiovasc Interv (2005) 66;597

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16208713

Impact of platelet glycoprotein IIb/IIIa inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provokable myocardial ischemia (a TAXUS IV substudy) P. S. Teirstein, J. Kao, M. Watkins, M. A. Tannenbaum, N. Laufer, M. Chang, R. Mehran, G. Dangas, M. E. Russell, S. G. Ellis and G. W. Stone

Am J Cardiol (2005) 96;500-5

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16098300

A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: factoring in new trials and meta-analysis data E. J. Topol

Am Heart J (2005) 149;S100-6

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16124950

Relation of anemia at discharge to survival after acute coronary syndromes J. Vaglio, D. M. Safley, M. Rahman, M. Kosiborod, P. Jones, R. Thompson, H. M. Krumholz and J. A. Spertus

Am J Cardiol (2005) 96;496-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16098299

Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial N. von Beckerath, D. Taubert, G. Pogatsa-Murray, E. Schomig, A. Kastrati and A. Schomig

Circulation (2005) 112;2946-50

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16260639

Aspirin and clopidogrel resistance: an emerging clinical entity T. H. Wang, D. L. Bhatt and E. J. Topol

Eur Heart J (2005)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16364973

Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation W. S. Weintraub, E. M. Mahoney, A. Lamy, S. Culler, Y. Yuan, J. Caro, S. Gabriel and S. Yusuf

J Am Coll Cardiol (2005) 45;838-45

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15766816

Stent thrombosis is associated with an impaired response to antiplatelet therapy P. Wenaweser and O. Hess

J Am Coll Cardiol (2005) 46;CS5-6

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16237868

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y₁₂ antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial S. D. Wiviott, E. M. Antman, K. J. Winters, G. Weerakkody, S. A. Murphy, B. D. Behounek, R. J. Carney, C. Lazzam, R. G. McKay, C. H. McCabe and E. Braunwald

Circulation (2005) 111;3366-73

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15967851

Different effect of Tirofiban and aspirin plus Clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion Y. Yuejin, Z. Jinglin, Y. Shijie, W. Yongjian, J. Zhicheng, Y. Weixian, M. Liang, W. Yanwu and G. Runlin

Heart (2005)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16387825

Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial U. Zeymer, R. Zahn, R. Schiele, W. Jansen, E. Girth, A. Gitt, K. Seidl, R. Schroder, S. Schneider and J. Senges

Eur Heart J (2005) 26;1971-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15857851